{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T10:51:40Z","timestamp":1787741500441,"version":"build-2784847793"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,22]],"date-time":"2021-07-22T00:00:00Z","timestamp":1626912000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,7,22]],"date-time":"2021-07-22T00:00:00Z","timestamp":1626912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurocrit Care"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1007\/s12028-021-01291-4","type":"journal-article","created":{"date-parts":[[2021,7,22]],"date-time":"2021-07-22T20:04:36Z","timestamp":1626984276000},"page":"240-247","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Clazosentan for Improvement of Time to Peak Perfusion in Patients with Angiographically Confirmed Severe Vasospasm"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4187-4949","authenticated-orcid":false,"given":"Austin","family":"Lai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Can Ozan","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Vranic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Weidauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thabele","family":"Leslie-Mazwi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua A.","family":"Hirsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajiv","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,22]]},"reference":[{"issue":"6","key":"1291_CR1","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1097\/00006123-200212000-00002","volume":"51","author":"M Chow","year":"2002","unstructured":"Chow M, Dumont AS, Kassell NF, et al. Endothelin receptor antagonists and cerebral vasospasm: an update. Neurosurgery. 2002;51(6):1333\u201342.","journal-title":"Neurosurgery"},{"issue":"11","key":"1291_CR2","doi-asserted-by":"publisher","first-page":"3015","DOI":"10.1161\/STROKEAHA.108.519942","volume":"39","author":"RL MacDonald","year":"2008","unstructured":"MacDonald RL, Kassell NF, Mayer S, et al. Clazosentan to overcome neurological ischemia and infarction occurring after subarachnoid hemorrhage (CONSCIOUS-1): randomized, double-blind, placebo-controlled phase 2 dose-finding trial. Stroke. 2008;39(11):3015\u201321.","journal-title":"Stroke"},{"issue":"1","key":"1291_CR3","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3171\/jns.2005.103.1.0009","volume":"103","author":"P Vajkoczy","year":"2005","unstructured":"Vajkoczy P, Meyer B, Weidauer S, et al. Clazosentan (AXV-034343), a selective endothelin A receptor antagonist, in the prevention of cerebral vasospasm following severe aneurysmal subarachnoid hemorrhage: results of a randomized, double-blind, placebo-controlled, multicenter phase IIa study. J Neurosurg. 2005;103(1):9\u201317.","journal-title":"J Neurosurg"},{"key":"1291_CR4","doi-asserted-by":"publisher","first-page":"e639","DOI":"10.1016\/j.wneu.2019.04.222","volume":"128","author":"RT Higashida","year":"2019","unstructured":"Higashida RT, Bruder N, Gupta R, et al. Reversal of vasospasm with clazosentan after aneurysmal subarachnoid hemorrhage: a pilot study. World Neurosurg. 2019;128:e639\u201348.","journal-title":"World Neurosurg"},{"issue":"3\u20134","key":"1291_CR5","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1159\/000468157","volume":"6","author":"C Donaldson","year":"2017","unstructured":"Donaldson C, O\u2019Neill AH, Slater L-A, Chong W, Lai LT, Chandra RV. Feasibility of real-time angiographic perfusion imaging in the treatment of cerebral vasospasm. Interv Neurol. 2017;6(3\u20134):163\u20139.","journal-title":"Interv Neurol"},{"key":"1291_CR6","unstructured":"R Core Team, R Foundation for Statistical Computing. R: A Language and Environment for Statistical Computing. 2019. http:\/\/www.r-project.org\/."},{"issue":"6","key":"1291_CR7","doi-asserted-by":"publisher","first-page":"110","DOI":"10.2307\/3002019","volume":"2","author":"FE Satterthwaite","year":"1946","unstructured":"Satterthwaite FE. An approximate distribution of estimates of variance components. Biometrics Bull. 1946;2(6):110.","journal-title":"Biometrics Bull"},{"issue":"3","key":"1291_CR8","first-page":"1","volume":"12","author":"LD Besheli","year":"2017","unstructured":"Besheli LD, Tan CO, Bell DL, Hirsch JA, Gupta R. Temporal evolution of vasospasm and clinical outcome after intra-arterial vasodilator therapy in patients with aneurysmal subarachnoid hemorrhage. PLoS ONE. 2017;12(3):1\u201312.","journal-title":"PLoS ONE"},{"issue":"11","key":"1291_CR9","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1007\/s00234-008-0424-4","volume":"50","author":"E Hattingen","year":"2008","unstructured":"Hattingen E, Blasel S, Dettmann E, et al. Perfusion-weighted MRI to evaluate cerebral autoregulation in aneurysmal subarachnoid haemorrhage. Neuroradiology. 2008;50(11):929\u201338.","journal-title":"Neuroradiology"},{"issue":"1","key":"1291_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00234-007-0294-1","volume":"50","author":"S Weidauer","year":"2008","unstructured":"Weidauer S, Vatter H, Beck J, et al. Focal laminar cortical infarcts following aneurysmal subarachnoid haemorrhage. Neuroradiology. 2008;50(1):1\u20138.","journal-title":"Neuroradiology"},{"issue":"6","key":"1291_CR11","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1161\/STROKEAHA.106.477976","volume":"38","author":"S Weidauer","year":"2007","unstructured":"Weidauer S, Lanfermann H, Raabe A, Zanella F, Seifert V, Beck J. Impairment of cerebral perfusion and infarct patterns attributable to vasospasm after aneurysmal subarachnoid hemorrhage: a prospective MRI and DSA Study. Stroke. 2007;38(6):1831\u20136.","journal-title":"Stroke"},{"issue":"4","key":"1291_CR12","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1097\/00004647-199804000-00010","volume":"18","author":"KD Yundt","year":"1998","unstructured":"Yundt KD, Grubb RL, Diringer MN, Powers WJ. Autoregulatory vasodilation of parenchymal vessels is impaired during cerebral vasospasm. J Cereb Blood Flow Metab. 1998;18(4):419\u201324.","journal-title":"J Cereb Blood Flow Metab"},{"key":"1291_CR13","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1161\/01.STR.31.7.1621","volume":"31","author":"H Ohkuma","year":"2000","unstructured":"Ohkuma H, Manabe H, Tanaka M, Suzuki S. Impact of cerebral microcirculatory changes on cerebral blood flow during cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Stroke. 2000;31:1621\u20137.","journal-title":"Stroke"},{"issue":"6","key":"1291_CR14","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1161\/STROKEAHA.111.648980","volume":"43","author":"RL MacDonald","year":"2012","unstructured":"MacDonald RL, Higashida RT, Keller E, et al. Randomized trial of clazosentan in patients with aneurysmal subarachnoid hemorrhage undergoing endovascular coiling. Stroke. 2012;43(6):1463\u20139.","journal-title":"Stroke"}],"container-title":["Neurocritical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12028-021-01291-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12028-021-01291-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12028-021-01291-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T16:22:50Z","timestamp":1643905370000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12028-021-01291-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,22]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["1291"],"URL":"https:\/\/doi.org\/10.1007\/s12028-021-01291-4","relation":{},"ISSN":["1541-6933","1556-0961"],"issn-type":[{"value":"1541-6933","type":"print"},{"value":"1556-0961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,22]]},"assertion":[{"value":"6 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This research has not received any specific grant from any funding agency in the public, commercial or not-for-profit sectors.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Source of Support"}},{"value":"RG and SW have been consultants and scientific advisors for Actelion Pharmaceuticals Ltd and Idorsia Pharmaceuticals Ltd and have received consulting fees. COT has been a consultant for Lokavant Inc and has received consulting fees. RG, SW, and JH served as members of the independent review committee on the REVERSE study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethical approval was obtained from the Partners Human Research Committee, Boston, USA. Reference number: 2014P002368.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval\/Informed Consent"}}]}}